Topiramate in patients with juvenile myoclonic epilepsy.
Arch Neurol
; 62(11): 1705-8, 2005 Nov.
Article
em En
| MEDLINE
| ID: mdl-16286543
ABSTRACT
BACKGROUND:
Topiramate is a broad-spectrum agent effective against primarily generalized tonic-clonic seizures (PGTCS) as well as partial-onset seizures. Juvenile myoclonic epilepsy is one of the most common idiopathic generalized epilepsies, with most patients experiencing PGTCS.OBJECTIVE:
To evaluate topiramate as add-on therapy in patients with juvenile myoclonic epilepsy.DESIGN:
Post-hoc analysis of a patient subset from 2 multicenter, double-blind, randomized, placebo-controlled, parallel-group trials.SETTING:
Eighteen centers in the United States; 10 centers in Europe; 1 center in Costa Rica (primary trials). PATIENTS A total of 22 patients with juvenile myoclonic epilepsy participating in placebo-controlled trials assessing topiramate (target dose, 400 mg/d in adults) in inadequately controlled PGTCS. MAIN OUTCOMEMEASURE:
Reduction of PGTCS.RESULTS:
A 50% or more reduction of PGTCS in 8 of 11 topiramate-treated patients (73%) and 2 of 11 placebo-treated patients (18%) (P = .03). Reductions in myoclonic, absence, and total generalized seizures were also observed, although topiramate vs placebo differences did not achieve statistical significance.CONCLUSION:
As a broad-spectrum agent, topiramate is an effective option for patients with juvenile myoclonic epilepsy.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Resultado do Tratamento
/
Epilepsia Mioclônica Juvenil
/
Frutose
/
Anticonvulsivantes
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Arch Neurol
Ano de publicação:
2005
Tipo de documento:
Article
País de afiliação:
Estados Unidos